Navigation Links
Novel Anti-Neutrophilic Effect produced by Salmeterol in mild asthma patients

A recent three-way crossover study over six weeks by clinicians at the National Heart and Lung Institute, Royal Brompton Hospital, London has shown that Salmeterol produced a novel anti-neutrophilic effect among patients with mild asthma. The study was prompted by the long standing argument about the effects of long-acting beta2-adrenergic receptor agonists, such as salmeterol, on inflammation. The clinicians enrolled 20 patients, between the ages// of 18 and 55, with mild stable asthma who were randomized to receive salmeterol (50 micrograms b.d), fluticasone propionate (250 micrograms b.d), or placebo. They investigated the effect of salmeterol on the numbers of inflammatory cells in biopsy samples of distinct immuno-phenotype and those expressing the genes for interleukin-4 and -5, regulatory cytokines which are particularly relevant to asthma.

The numbers of neutrophils in bronchial biopsy samples and the concentrations of myeloperoxidase and soluble E-selectin in serum, each of which reflect neutrophil involvement, was found to be significantly reduced in subjects who were given salmeterol compared to those who were given the placebo. Salmeterol, compared with fluticasone propionate, reduced neutrophil number and human neutrophil lipocalin level in bronchial lavage fluid, and intercellular adhesion molecule-1 level in bronchoalveolar lavage fluid. It was also observed that the numbers of (CD3+) T-lymphocytes, (CD4+) T-helper cells, (CD45RO+) activated T-helper cells and eosinophils in the biopsy samples were significantly reduced with fluticasone propionate, compared with placebo. Fluticasone propionate also reduced the percentage of eosinophils and soluble intercellular adhesion molecule-1 in serum.

The clinicians also found that after the use of salmeterol, as compared with both fluticasone propionate and placebo, the airways hyper-responsiveness and the percentage of symptom-free days and nights improved significantly.


'"/>




Page: 1

Related medicine news :

1. Novel "CYCLOSPORINE CAPSULE FORMULATION" to be launched
2. Novel biopsy technique for prostate cancer
3. Novel computer model for breast cancer
4. Novel research on liver cancer
5. Novel way to fight cancer
6. Novel test for bowel cancer
7. Novel Therapy for Chronic Problem
8. Blood Sugar Kept In Control By Novel Protein
9. Novel antibiotic dressing developed for improved wound healing
10. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
11. Novel drug holds promise for treatment of Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/13/2019)... ... 2019 , ... Diameter Health , the leader in clinical data normalization ... Management Act (FISMA) High General Support System Authority to Operate (ATO) for Diameter Health’s ... for the VA because of their work with confidential patient data. Protecting this data ...
(Date:2/13/2019)... ... ... Castle announced today that it has raised $9.2M in Series A funding from ... First Round and F-Prime Capital Partners . Angel investors joining the round ... Networks, and Olivier Pomel, CEO at Datadog. This round brings the company’s total funding ...
(Date:2/13/2019)... ... 13, 2019 , ... American Vision Partners, one of the ... a new addition to their growing list of ophthalmology brands: Visage Aesthetics & ... ophthalmology practice. , Dr. Zachary Berbos, MD, FACS, and Dr. Grant ...
(Date:2/13/2019)... ... ... A Place at Home has received the 2019 Best of ... Choice Award is granted only to the top-ranking home care providers, based on caregiver ... care. A Place at Home is ranked among the best employers of in-home caregivers ...
(Date:2/13/2019)... ... 2019 , ... Surgery that moves both jaws forward – known as maxillomandibular ... (OSA), resulting in benefits that include improved breathing, daytime wakefulness and quality of life, ... should be regarded as the preferred treatment for patients with moderate to severe OSA ...
Breaking Medicine News(10 mins):
(Date:2/14/2019)... ... February 14, 2019 , ... San ... UroLift® Center of Excellence. The designation recognizes that Dr. Peterson has achieved a ... commitment to exemplary care for men suffering from symptoms associated with Benign Prostatic ...
(Date:2/13/2019)... ... February 14, 2019 , ... Entomol’s ... approval by the California EPA for release and sale within the state. California ... major milestone in Entomol‘s commercial development. This registration opens the door for wholesale/retail ...
(Date:2/13/2019)... ... 13, 2019 , ... NCPDP announced today that Jim Carroll, ... Wednesday, May 8, at its 2019 Annual Technology & Business Conference. Themed Dare ... Spa in Scottsdale, Arizona, and is expected to draw more than 700 attendees ...
Breaking Medicine Technology: